Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akebia Therapeutics

2.40
+0.14006.19%
Pre-market: 2.32-0.0800-3.33%05:51 EDT
Volume:4.62M
Turnover:10.59M
Market Cap:566.40M
PE:-10.50
High:2.40
Open:2.25
Low:2.18
Close:2.26
Loading ...

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

GlobeNewswire
·
06 Mar

Akebia Therapeutics (NASDAQ:AKBA investor five-year losses grow to 80% as the stock sheds US$55m this past week

Simply Wall St.
·
27 Feb

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Feb

Akebia Therapeutics Price Target Maintained With a $7.50/Share by HC Wainwright & Co.

Dow Jones
·
24 Jan

Akebia Therapeutics Price Target Maintained With a $7.50/Share by HC Wainwright & Co.

Dow Jones
·
15 Jan

Akebia Therapeutics: Strong Market Position and Growth Potential Justifies Buy Rating

TIPRANKS
·
15 Jan

Akebia announces ‘multiple positive business updates’

TipRanks
·
14 Jan

Akebia Therapeutics Inc: Vafseo Tablets NOW Shipping in U.S.

THOMSON REUTERS
·
13 Jan

Akebia Therapeutics Announces Multiple Positive Business Updates

PR Newswire
·
13 Jan

New Strong Sell Stocks for January 3rd

Zacks
·
03 Jan

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
03 Jan

High Growth Tech Stocks To Watch In December 2024

Simply Wall St.
·
21 Dec 2024

New Strong Sell Stocks for December 5th

Zacks
·
05 Dec 2024

BRIEF-U.S. Renal Care Enrolls First Patients In The Voice Collaborative Clinical Trial Of Vafseo® (Vadadustat) For CKD Patients On Dialysis

Reuters
·
03 Dec 2024

Akebia: U.S. Renal Care enrolls first patient in its VOICE collaborative trial

TIPRANKS
·
03 Dec 2024

Akebia Therapeutics Inc - Vafseo Expected to Be Available in U.S. in January 2025

THOMSON REUTERS
·
03 Dec 2024